Genesystem KRX:363250KOSDAQ
진시스템 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days2
Articles tracked1since Sep 11
In Q2 2026, Genesystem reported revenue of ₩432m, up 523.0% year on year, and an operating loss of ₩958m. Genesystem (진시스템) appeared in 1 Korean news article and 2 DART filings over the past seven days. Coverage peaked on Sep 30 with 1 article.
Filing signals Asset deal Dilution risk 4 quarters of losses Screener
Genesystem quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩432m | +523.0% | −₩958m margin −221.7% | −₩814m |
| Q1 2026 | ₩329m | +419.0% | −₩1.6bn | −₩1.6bn |
| Q4 2025 derived | ₩158m | +29.4% | −₩3.0bn | −₩8.2bn |
| Q3 2025 | ₩90m | -88.8% | −₩2.3bn | −₩2.2bn |
| Q2 2025 | ₩69m | -52.7% | −₩2.4bn | −₩2.4bn |
| Q1 2025 | ₩63m | -53.1% | −₩2.0bn | −₩1.9bn |
| Q4 2024 derived | ₩123m | +84.9% | −₩3.3bn | −₩3.1bn |
| Q3 2024 | ₩803m | +293.8% | −₩2.1bn margin −263.3% | −₩2.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Genesystem top stories 2 weeks, by number of outlets
- 1